Evoke Pharma, Inc. (EVOK)
After hours:
| Previous close | 1.8600 |
| Open | 1.9100 |
| Bid | 1.4500 x 3000 |
| Ask | 2.0900 x 1400 |
| Day's range | 1.9000 - 1.9900 |
| 52-week range | 1.3720 - 16.8000 |
| Volume | |
| Avg. volume | 35,077 |
| Market cap | 6.352M |
| Beta (5Y monthly) | 0.40 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.3600 |
| Earnings date | 08 May 2023 - 12 May 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 7.00 |
- GlobeNewswire
Evoke Pharma & EVERSANA Announce Compelling Real-World Data on the Impact of GIMOTI in Reducing the Utilization of Healthcare Resources to be Presented at the Academy of Managed Care Pharmacy (AMCP) 2023
Data Demonstrated Reduced Use of Healthcare Resources among Patients Treated with GIMOTI Image 1 All-Cause HCRU in the Pre-nasal MCP period vs. Post-nasal MCP period Image 2 Nausea, Vomiting, and DGP-associated HCRU in the Pre-nasal MCP period vs. Post-nasal MCP Period SOLANA BEACH, Calif., March 23, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclo
- GlobeNewswire
Evoke Pharma Reports Fourth Quarter and Full Year 2022 Financial Results
Fiscal year 2022 net product sales from prescriptions increased by 179% to $2.5 million versus 2021Patient enrollment increased by 149% compared with 2021 SOLANA BEACH, Calif., March 21, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, today announced its financial results for the fourth quarter and full year ended December 31,
- GlobeNewswire
Evoke Pharma to Report Fourth Quarter and Full Year 2022 Results on March 21, 2023
SOLANA BEACH, Calif., March 15, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, today announced that the Company is scheduled to release its fourth quarter and full year 2022 financial results on Tuesday, March 21, 2023, after the market closes. Management will host a conference call on Tuesday, March 21, 2023, at 4:30 p.m. ET
